Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterization and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.

Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.

Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.

Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.

Abstract: The present invention relates to a method for the diagnosis and/or risk stratification of neuromyelitis optica (abbreviated NMO), wherein a determination from a body sample of a patient/test subject is performed by means of artificial aquaporin-4 peptides. The invention further relates to a kit and to new artificial aquaporin-4 peptides as such.

Abstract: The invention relates to the use of polycycloolefins in electronic devices and more specifically to the use of such polycycloolefins as interlayers applied to insulating layers used in electronic devices, the electronic devices that encompass such polycycloolefin interlayers and processes for preparing such polycycloolefin interlayers and electronic devices.

Abstract: The present invention relates to a novel method for diagnosing high-affinity binders, in particular antibodies or autoantibodies, and the identification, characterisation and selection of marker sequences and diagnostic use thereof, in particular in the form of a panel. The invention also relates to a singleplex assay in which the discovered selection of marker sequences is used in the form of a panel and high-affinity binders are detected using a single signal.

Abstract: The invention relates to novel marker sequences for systemic lupus erythematosus and to the use thereof in diagnosis as well as to a method for screening potential active ingredients for systemic lupus erythematosus diseases using said marker sequences. The invention further relates to a diagnostic device containing such marker sequences for systemic lupus erythematosus, especially to a protein biochip and the use thereof.

Abstract: The invention relates to the use of polycycloolefins in electronic devices and more specifically to the use of such polycycloolefins as interlayers applied to insulating layers used in electronic devices, the electronic devices that encompass such polycycloolefin interlayers and processes for preparing such polycycloolefin interlayers and electronic devices.

Abstract: The invention relates to novel marker sequences for Alzheimer's disease, in particular Alzheimer's dementia, and their diagnostic use including a screening method in order to identify potential drugs for the treatment/prophylaxis of Alzheimer's disease by means of the said novel marker sequences. Moreover, the invention relates to a diagnostic device comprising said novel marker sequences for diagnosing Alzheimer's disease, particularly a protein array (chip) and its use hereto.

Abstract: The present invention relates to a system of protein binders containing at least one protein binder presented in at least one native form and at least one non-native form and its use including a method for discrimination and/or differential screening of suitable protein binders in native and non-native form.

Abstract: The invention relates to new butane acid derivatives comprising a cyanide group, pharmaceutical compositions containing said butane acid derivatives and the use of said butane acid derivatives in the production of pharmaceutical compositions for treating various illnesses.

Abstract: The invention relates to the use of a substance being selected from the group consisting of “sugar phosphates, sugar phosphate analogs, amino acids, amino acid analogs, and mixtures of said substances” for producing a pharmaceutical composition for reducing weight and/or preventing delayed damage caused by diabetes mellitus by modulating the association p36/malate dehydrogenase and/or transaminases.

Abstract: The invention relates to new butane acid derivatives comprising a cyanide group, pharmaceutical compositions containing said butane acid derivatives and the use of said butane acid derivatives in the production of pharmaceutical compositions for treating various illnesses.

Abstract: A method for disrupting frozen cells and/or tissue in a solid, frozen state in the presence of a solid denaturing substance is provided. The method comprises providing frozen cells and/or tissue in frozen solid form, adding thereto the solid denaturing substance in sold form, and applying mechanical force thereto for disruption of the frozen cells and/or tissue. The frozen cells and/or tissue include muscle cells and/or muscle tissue, wheat cells and/or wheat tissue, and maize cells and/or maize tissue. Further, the solid, denaturing substance in solid form is a crystalline substance and can be selected from urea, thiourea, guanidium chloride, guanidium thiocyanate and ammonium sulfate. Also the solid, denaturing substance in solid form is added to the frozen cells and/or tissue in frozen form in an approximately 1 to 20 fold (w/w) excess.

Abstract: The invention relates to an insect cell vector for the production of proteins from the DEAD protein family.

Abstract: A combination preparation comprising a compound which has a phosphodiesterase-inhibiting action, and a compound which reduces the biologically effective intracellular Ca2+ content, is suitable for the treatment of immunological diseases.

Abstract: A compound of the formula where R1 is the radical of the formula II or III is suitable for the production of a pharmaceutical for the treatment of inflammations, carcinomatous diseases, or autoimmune diseases. A compound of the formula IV is suitable for the production of specific antibodies against a compound of the formula I for the discovery of specific-binding proteins from cell extracts, serum, blood, or synovial fluids, for the purification of proteins, for the modification of microtiter plates, or for the preparation of chromatography material, in particular of affinity chromatography material, and for use in diagnostics.

Abstract: Preparation of microorganisms comprising omega-3-fatty acids for use as a prophylactic or therapeutic agent against parasitic diseases of animalsThe present invention relates to the use of a preparation of microorganisms containing omega-3-fatty acid for preparing a medicament for prophylactic and therapeutic use against a parasitic disease of animals.

Abstract: A compound of the formula ##STR1## where R.sup.1 is the radical of the formula II or III ##STR2## is suitable for the production of a pharmaceutical for the treatment of inflammations, carcinomatous diseases, or autoimmune diseases. A compound of the formula IV ##STR3## is suitable for the production of specific antibodies against a compound of the formula I for the discovery of specific-binding proteins from cell extracts, serum, blood, or synovial fluids, for the purification of proteins, for the modification of microtiter plates, or for the preparation of chromatography material, in particular of affinity chromatography material, and for use in diagnostics.